IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Endocare, Inc. has been named to Deloitte’s prestigious Technology Fast 50 program for Orange County, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation’s leading professional services organizations. Rankings are based on the percentage of revenue growth over five years from 2001 to 2005.
This year’s Orange County Technology Fast 50 program is co-presented by Deloitte & Touche USA LLP and Porsche Motorsport, Continental Airlines, DLD Insurance, McDermott & Bull, Comerica, Stradling Yocca Carlson & Rauth, Cresa Partners and Merrill Corporation, in association with AeA and the Technology Council of Southern California.
Endocare’s Chairman and CEO Craig T. Davenport credits the Company’s dedicated employees and a world class medical technology platform for the Company’s 117 percent revenue growth from 2001 to 2005. Davenport said, “It is a great time to be at Endocare. The growing adoption of cryoablation for treating a variety of cancers combined with the recent resolution of historical regulatory matters has cleared our path toward continued progress and growth. This award is a tribute to all of our employees, customers and partners.”
Endocare’s increase in revenues of 117 percent from 2001 to 2005 resulted in a 25 ranking in the Technology Fast 50 for Orange County. The average increase in revenues among companies who made the Technology Fast 50 for this region was 642.5 percent.
“To rank on Deloitte’s Technology Fast 50, companies must have phenomenal revenue growth over five years,” said Rick Rayson, Managing Partner, Deloitte & Touche LLP in Orange County. “Endocare has proven to be one of the fast-growth success stories in Orange County, and we applaud its dedication to making its vision a reality.”
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company’s operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies’ technology or intellectual property in a unique way does not qualify.
Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Technology Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte’s Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.
About Endocare
Endocare, Inc. -- www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names “Deloitte”, “Deloitte & Touche”, “Deloitte Touche Tohmatsu” or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.
Investor Contact: Matt Clawson Allen & Caron, Inc. (949) 474-4300 matt@allencaron.com Media Contact: Len Hall Allen & Caron, Inc. (949) 474-4300 len@allencaron.com For Additional Information: Craig T. Davenport, CEO Michael R. Rodriguez, CFO Endocare, Inc. (949) 450-5400
Endocare, Inc.
CONTACT: Investors, Matt Clawson, matt@allencaron.com, or Media, Len Hall,len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, forEndocare, Inc.; or Craig T. Davenport, CEO, or Michael R. Rodriguez, CFO,both of Endocare, Inc., +1-949-450-5400
